← Back to Search

Nonsteroidal Anti-inflammatory Drug

Naproxen + Aspirin for Lynch Syndrome

Phase 2
Recruiting
Led By Eduardo Vilar-Sanchez, MD
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age ≥18 years.
Willing to undergo yearly standard of care screening colonoscopy for the duration of the clinical trial.
Must not have
Individuals with active gastroduodenal ulcer disease in the preceding 5 years.
Individuals with history of myocardial infarction, stroke, coronary-artery bypass draft, invasive coronary revascularization in the preceding 5 years.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Summary

This trial is studying the effects of two drugs, naproxen and aspirin, on the normal colon in people with Lynch Syndrome.

Who is the study for?
Adults over 18 with Lynch Syndrome, a condition predisposing them to colorectal cancer, can join this trial. They must have normal organ and marrow function, not be pregnant or breastfeeding, agree to use contraception if applicable, and refrain from NSAIDs during the trial. Those with recent cancers or major surgeries are excluded.
What is being tested?
The study is testing whether naproxen or aspirin could help prevent cancer in people with Lynch Syndrome by looking at their colon's response. Participants will randomly receive either drug and undergo regular colon examinations to track changes.
What are the potential side effects?
Naproxen and aspirin may cause gastrointestinal issues like ulcers or bleeding, allergic reactions for those sensitive to NSAIDs, kidney problems in susceptible individuals, and increased risk of heart-related events.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.
Select...
I am willing to have a yearly colonoscopy for the trial period.
Select...
I have Lynch syndrome, confirmed by genetic testing or my medical history.
Select...
Part of my lower colon or rectum is intact and can be examined with an endoscope.
Select...
You must have normal levels of red and white blood cells, platelets, and other blood indicators, as well as normal kidney and liver function.
Select...
I agree not to take aspirin, NSAIDs, or COX-inhibitors during the trial.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have not had an active stomach or upper small intestine ulcer in the last 5 years.
Select...
I have had a heart attack, stroke, or heart surgery in the last 5 years.
Select...
I do not have uncontrolled kidney problems.
Select...
I am not pregnant, breastfeeding, or if capable of becoming pregnant, I am willing to use reliable contraception.
Select...
I do not have any uncontrolled illnesses that could interfere with the study.
Select...
I have had surgery to remove my entire colon and rectum.
Select...
My tumor has specific genetic changes in the MMR genes.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Side effects data

From 2014 Phase 4 trial • 323 Patients • NCT01587274
6%
Nausea/ vomiting
5%
Stomach irritation
4%
Dizziness
4%
Drowsiness
3%
Other
100%
80%
60%
40%
20%
0%
Study treatment Arm
Naproxen Alone
Opioid
Skeletal Muscle Relaxant

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: NaproxenExperimental Treatment1 Intervention
Participants will take two (2) naproxen matching capsules by mouth 1 time every day, at about the same time each day
Group II: AspirinActive Control1 Intervention
Participants will take two (2) aspirin matching capsules by mouth 1 time every day, at about the same time each day
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Naproxen
FDA approved

Find a Location

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor
3,039 Previous Clinical Trials
1,799,661 Total Patients Enrolled
National Institutes of Health (NIH)NIH
2,765 Previous Clinical Trials
8,133,471 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,842 Previous Clinical Trials
41,002,960 Total Patients Enrolled

Media Library

Aspirin (Nonsteroidal Anti-inflammatory Drug) Clinical Trial Eligibility Overview. Trial Name: NCT05411718 — Phase 2
Colorectal Cancer Research Study Groups: Naproxen, Aspirin
Colorectal Cancer Clinical Trial 2023: Aspirin Highlights & Side Effects. Trial Name: NCT05411718 — Phase 2
Aspirin (Nonsteroidal Anti-inflammatory Drug) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05411718 — Phase 2
~17 spots leftby Nov 2025